(September 9, 2021, 10:44 AM EDT) -- ALEXANDRIA, Va. — A recently issued patent claiming formulations that comprise a vascular endothelial growth factor (VEGF) antagonist fusion protein suffers from inadequate written description or, alternatively, would have been obvious to a person of skill in the art (POSA), a petitioner for post-grant review tells the Patent Trial and Appeal Board in a Sept. 7 petition....